CLLS
CellectisANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull: favorable clinical readouts, strategic partnerships, or non-dilutive financing create visible commercialization paths and re-rate the ADR toward mid-single-digit levels.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Adverse clinical safety/efficacy readouts or enrollment delays
Momentum
95
Value
44
Sentiment
68
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.01 · Bull $5.35 · Bear $2.67
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-10-08 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $7.50
Why
Momentum95 · Δ7d -
Value44 · Δ7d +0.1
Sentiment68 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
95
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
44
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
68
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade A. Momentum 95.1 / Value 44.0 / Sentiment 67.8
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$248.15M
Beta
2.83
Shares Out
72.33M
P/E (TTM) · Derived
-9.8
P/S (TTM)
4.01
P/FCF (TTM)
17.30
Rev YoY
+105.9%
EPS YoY
+102.5%
Gross Margin
-
Op Margin
-32.0%
Net Debt
-$166.79M
Current Ratio
1.49
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology